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Sequential effects of cyclosporine therapy on blood pressure, renal
function and neurohormones. We have studied the sequential effects of
cyclosporine during the first four days after its initiation in an effort to
elucidate the primary and secondary events in the pathogenesis of
cyclosporine induced nephrotoxicity and hypertension. Knowledge
about the earliest effects of cyclosporine provides a more logical
approach for devising therapeutic strategies to counteract nephrotox-
icity and hypertension. On day 1, cyclosporine acutely increased
systemic BP and decreased urine volume. Plasma renin activity was
suppressed by day 2 and remained so thereafter. Renal sodium excre-
tion was not affected until day 4 at which point a natriuresis occurred.
Cyclosporine exerted a more marked antidiuretic effect on day 4
compared to day 1, which was augmented by a physiological infusion of
vasopressin. Over the first four days of therapy, glomerular filtration
rate and effective renal plasma flow were unchanged. Our data show
that cyclosporine induced hypertension in the initial stages is not
sodium dependent, and that changes in renal water handling were not
dependent on alterations in the glomerular filtration rate or effective
renal plasma flow. tn fact, a natriuresis occurred which was most likely
due to a combination of pressure natriuresis and angiotensin II suppres-
sion. The cyclosporine induced antidiuresis may indicate a distal
nephron effect since cyclosporine augmented the antidiuretic effect of
vasopressin, although vasopressin levels per se were not increased by
cyclosporine alone.
Cyclosporine is an important immunosuppressive agent
which has revolutionized organ transplantation. It is now in-
creasingly being used outside the field of organ transplantation,
particularly in the treatment of psoriasis, dermatitis [1] and
rheumatoid arthritis [2]; more recently it is also being utilized in
therapeutic trials for asthma [3] and multiple myeloma [4].
Unfortunately, its important clinical side-effects of nephrotox-
icity and hypertension prevent its more widespread usage.
Acute cyclosporine nephrotoxicity is characterized by a fall
in glomerular filtration rate (GFR) and renal blood flow (RBF).
It affects all patient groups treated with cyclosporine, including
renal transplant recipients [5], other transplant recipients [6]
and non-transplant patients [7, 81. If cyclosporine is stopped
within a three-month period these functional renal effects are
reversible [9], but continued treatment results in irreversible
anatomical changes of chronic cyclosporine nephropathy [10].
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An important early renal event preceding frank renal dysfunc-
tion appears to be renal vasoconstriction [11], particularly of
the afferent arteriole [12]. The etiology of the vasoconstrictive
action of cyclosporine is unclear, but alterations in the renin-
angiotensin-aldosterone system [13], prostaglandin-thrombox-
ane imbalance [14], endothelin [15] and sympathetic nervous
system activation [16] have all been suggested.
Hypertension is also a common, though not invariable,
occurrence with cyclosporine and 60% of patients are said to
develop cyclosporine induced hypertension [17]. The changes
in blood pressure are reversible on cessation of cyclosporine
[11], and there is good evidence that the hypertension is sodium
dependent in the long term [18]. This has led Luke [19] to
propose a unifying theory for cyclosporine side-effects, namely
that renal vasoconstriction not only predisposes to nephrotox-
icity, but also results in proximal tubular sodium reabsorption
and thus an expansion of extracellular fluid volume and the
development of sodium dependent hypertension.
Most studies concerned with cyclosporine induced nephro-
toxicity and hypertension have been conducted after at least
one and often after several months of therapy with cyclospo-
rine, at which time renal vasoconstriction and hypertension are
well established. Clearly, it is important to elucidate what are
the initial and what are the later, possibly secondary, events in
the pathogenetic cascade leading to nephrotoxicity and hyper-
tension in order to test the hypothesis of Luke. We therefore
studied the effects of cyclosporine during its first four days of
administration to normal healthy men with no renal impairment.
Such an in vivo human model should outline the earliest
hormonal, renal and blood pressure changes which cyclospo-
rine produces. The advantage of this normal volunteer ap-
proach is that the confusion surrounding the early effects of
cyclosporine can be unraveled in the absence of confounding
variables such as coincidental disease, other drugs and postop-
erative fluid imbalance, the latter being particularly problematic
in transplant patients.
Methods
Eight normal, healthy, salt-replete male volunteers (age 23.4
2.5 years; wt 77.2 2.8 kg) were recruited into study 1, and
10 similar volunteers (age 22.2 1.1 years, wt 70.1 2.8 kg)
into study 2 after a full medical history and examination,
hematological and biochemical screening and after they had
given written informed consent. Subjects had no illness and
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were taking no medications whatsoever. These studies were
approved by the local committee on medical ethics.
All subjects were given advice regarding salt intake (l50
mEq Na, 60 to 80 mEq K) to adhere to for two days before
and during each study session. They were asked to refrain from
alcohol consumption and sexual intercourse for the same time
period, the latter in order to allow us to measure urine pros-
taglandins.
Study I
This was a double-blind, placebo-controlled randomized
crossover study. It consisted of two four-day treatment ses-
sions. Either cyclosporine (15 mglkg on days 1 to 3; 20 mg/kg on
day 4) (Sandimmun, Sandoz UK, Frimley Business Park,
Camberley, Surrey, UK) or placebo was taken for four days. A
two-week washout period was observed between study ses-
sions.
On days 1 and 4 of each study session, subjects arrived fasted
at 8:00 a.m. and were waterloaded with 20 mI/kg water over a 30
minute period following a standard regimen [201. Also, at 8:00
a.m. a PAH (aminohippurate sodium, MSD, West Point, Penn-
sylvania, USA) and inulin (mutest, Laevusan-Gessellschaft,
mbH, Linz, Austria) bolus (2 g PAH; 32.5 g inulin) followed by
an infusion (900 mg hr' PAH; 1.5 g hC' inulin) was com-
menced via a cannula in the right antecubital vein in order to
achieve plasma concentrations of 20 and 2.5 mg/dl, respec-
tively. A 90 minute equilibration was allowed prior to com-
mencement of the study. The treatment drug (either cyclospo-
Fine or placebo) was then given with a high fat meal (15 g fat) to
aid absorption. Twenty-minute renal clearance periods were
observed for the next three hours with subjects voiding their
urinary bladders completely every 20 minutes and being given
the equivalent volume of water to drink. Aliquots of urine were
saved for PAH, inulin and electrolyte determination. Blood was
taken at the midpoint of each period for PAH, inulin and
electrolytes. Blood pressure was measured every 20 minutes
during this study period using a semi-automated sphygmoma-
nometer (Dinamap vital signs monitor 1846, Critikon, Florida,
USA) and at noon on days 2 and 3.
Blood was taken for plasma renin activity, aldosterone,
angiotensin II, vasopressin and ANP levels after 30 minutes of
rest before and after the study sessions on day 1 and 4, and also
before the blood pressure recordings on days 2 and 3. Cyclo-
sporine levels were measured hourly during the three hour
sessions of day 1 and 4. Twenty-four-hour urine collections
were taken between study visits 1 and 4.
Study 2
This was a double-blind, placebo-controlled randomized
crossover study. Subjects were given either placebo or cyclo-
sporine (18 mg/kg) for four days; on the fourth day, subjects
arrived fasted at 8:00 a.m. and were waterloaded with 20 mI/kg
water over a 30 minute period as previously. PAH and inulin
infusions were begun as before and a 90-minute equilibration
period was allowed before commencement of the study. The
treatment drug was again given with a high fat breakfast, and
after three 20-minute renal clearance periods either a vasopres-
sin infusion (Pitressin, Parke Davis, Usk Road, Pontypool,
Gwent, UK) at 3 pg/kg/mm or an equivalent saline infusion as
placebo was run for the following two hours, during which
Table 1. Whole blood cyclosporine levels (ng/ml)
Study 1 Study 2 , day4
Time Cyclosporine/ Cyclosporine/
mm Day I Day 4 placebo vasopressin
0 0 0 229 14 197 13 241 34
60 494 152 1187 105 1355 227 1653 195
120 1476 136 1788 116 1871 200 2008 210
180 1243 162 1925 137 1944 178 2042 183
20-minute renal clearance periods were again performed. Blood
samples were collected and blood pressure was recorded as per
study 1.
Laboratory methods
Plasma and urine Na and K were measured by flame
photometry (Instrumentation Laboratory, Milan, Italy) while
osmolalities were measured by a cryoscopic osmometer (Gono-
tec, Berlin, Germany). Commercially available radioimmuno-
assay kits were used to measure whole blood cyclosporine
levels (monoclonal antibody) (Cyclo-Trac, Incstar Corp., Still-
water, Minnesota, USA), plasma aldosterone levels (Diagnostic
Products Corporation, 22 Blacklands Way, Oxon, 0X13 1DY,
Abingdon, UK), plasma renin activity (by generation of angio-
tensin I at 37°C for 90 minutes) (Incstar Corp.) and plasma atrial
natriuretic peptide (ANP) levels (Amersham International plc,
Aylesbury, UK). Plasma vasopressin levels were assayed by
the laboratories of Professor P.H. Baylis (Endocrine Unit,
Royal Victoria Infirmary, Newcastle-upon-Tyne, UK) using
their own RIA with a limit of detection of 0.3 pmol AVP/liter
plasma and intra-assay and interassay coefficients of variation
of 9.7% and 15.3%, respectively, at 2 pmol/liter [211. Plasma
and urine PAH and inulin concentrations were analyzed by the
method in [221. Urinary prostaglandin E2 (PGE2) was assayed
using a commercially available kit (Amersham).
Calculations
Mean arterial pressure was calculated by adding pulse
pressure to diastolic pressure and is expressed in mm Hg.
Glomerular filtration rate (GFR) and effective renal plasma
flow (ERPF) were estimated from clearances of inulin and
PAH, respectively, and were corrected for body surface area
and expressed as mi/mm. Clearance is defined as UV/P where U
is urinary concentration, V is urine volume, and P is plasma
concentration.
Renal vascular resistance (RVR) was obtained by dividing
(mean arterial pressure x 100) by renal blood flow (RBF) and is
expressed as mm Hg/mllmin. RBF was calculated by dividing
ERPF by (1 —Hematocrit).
Free water clearance (CH20) was calculated by subtracting
osmolar clearance (Cosm) from the total urine volume pro-
duced.
Estimates of tubular function were also calculated. The
filtered load of sodium (NaF) was calculated by multiplying
GFR by plasma Na (PNa). Sodium reabsorption in diluting
segments (NaRDil) was obtained by multiplying CH2O by Na•
Delivery of Na to diluting segments (NaDel) was obtained by
adding NaRDiI to the sum of UNaV and UKV, The fractional
sodium reabsorption in the diluting segments (NaRDiI %) was
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Table 2. Effects of cyclosporine and placebo on electrolyte handling
Dayl Day4
Placebo Cyclosporine Placebo Cyclosporine
Pre Post Pre Post Pre Post Pre Post
NaF 14966 14532 13653 13591 14881 14400 14227 13521
mmol/min (13943—15989) (13504—15561) (12227—15078) (12411—14771) (13655—16107) (13184—15616) (13061—15393) (12270—14772)
UNaV 163 187 213 245 173 159 290k 372
mmo!/min (127—200) (144—230) (157—269) (181—311) (131—215) (126—192) (194—386) (261—483)
NaRDi1 1923 1673 1952 1673 2099 1831 16l7 l157
mmollmin (1688—2158) (1375—1971) (1608—2296) (1415—1931) (1808-2390) (1624—2038) (1370-1864) (980—1334)
NaDel 2168 1955 2210 2013 2314 2050 1991 l576
mmol/min (1919—2417) (1649—2261) (1840—2580) (1743—2283) (2012—2616) (1844—2256) (1750—2232) (1398—1754)
NaDil % 88.5 84.6 88.0 81.5 90.3 88.9 799a 72.7k
(86.7—90.2) (82.0—87.2) (85.7—90.3) (76.5—86.5) (88.8—91.8) (86.9—90.9) (74.7—85.1) (65.8—79.6)
NaProx% 85.4 86.6 83.2 84.7 84.2 85.6 85.6 88,0b
(83.8—87.0) (84.9—88.3) (80.3—86.1) (82.2—87.2) (82.3—86.1) (84.2—87.0) (83.6—87.6) (86.4—89.6)
FENa* 0.013 0.015 0.016 o.02r 0.011 0.012 0,023a 0.028a
(0.007—0,019) (0.009—0.021) (0.008—0.024) (0.013—0.029) (0.007—0.015) (0.006—0.018) (0.009—0.037) (0.010—0.046)
UKV 52.5 50.5 48.4 57.3 52.1 61.6 52.7 77.0
mmol/min (35.2—69.7) (35.4—65.6) (26.9—69.9) (34.9—79.7) (22.0—82.1) (398—83.4) (29.3—76.1) (50.8—103.2)
FEK+ 0.136 0.158 0.137 0.180 0.132 0.152 0.154 0.208
(0.067—0.205) (0.078—0.238) (0.057—0.217) (0.086—0.274) (0.022—0.242) (0.076—0.228) (0.060—0.248) (0.094—0.322)
a P < 0.05 vs. placebo.bP < 0.05 vs. cyclosporine day 1.
obtained by dividing NaRDi1 by NaDel and multiplying by 100.
Finally, the fractional Na reabsorption in the proximal tubules
was calculated by the formula [(NaF — NaDel) ÷ NaF] x 100.
These estimates of segmental tubular function were adopted
from a paper by Balletta et al [231.
Statistical analysis
For the renal parameters, data are presented as a predrug,
corresponding to the average of three consecutive renal clear-
ance periods after the equilibration period and before the study
drug was given, and "peak drug effect" as the average of three
consecutive renal clearance periods for each individual subject
compared to the equivalent periods on placebo days. The
coefficient of variation was checked to ensure no anomalous
results. For the GFR these were 1.3% (placebo pre-day 1), 2.9%
(placebo post-day 1), 3.7% (placebo pre-day 4) and 1.7%
(placebo post-day 4), and 5.9% (cyclosporine pre-day 1), 7.6%
(cyclosporine post-day 1), 6.0% (cyclosporine pre-day 4) and
5.1% (cyclosporine post-day 4). Similarly, for ERPF, these
were 2.5%, 4.1%, 4.2% and 1.6% for placebo and 10.3%, 6.6%,
6.0% and 3.9% for cyclosporine.
Results
The findings of studies 1 and 2 are outlined separately for
clarity. The daily changes in blood pressure, hormone and
kidney function are documented for Study 1 while simply day 4
data from study 2 are given.
Cyclosporine levels
Whole blood cyclosporine levels for studies 1 and are
shown in Table 1.
Study I
Renal water and electrolyte handling. Compliance of the diet
was assessed by a 24-hour urine collection prior to each study
day which found sodium excretion to be 121 (91 to 151)
mmollday pre-placebo and 118 (94 to 142) mmollday pre-
cyclosporine (Tables 2, 3 and 4). Potassium excretion was 56
(48 to 64) and 44 (34 to 54), respectively.
Cyclosporine induced a significant antidiuretic effect which
was most pronounced after the waterloading regimen, and was
not a consistent finding over full 24-hour periods. At day 2,
24-hour urine volumes were significantly lower than placebo,
but this seemed to be due to increased urine output on placebo
rather than antidiuresis induced by cyclosporine. Urine osmo-
lality rose as urine volumes fell and thus free water clearance
declined.
A natriuresis occurred by day 4 of cyclosporine therapy
which was associated with no net change in NaF, but there was
a significant reduction in distal sodium reabsorption to account
for this. Potassium output remained unchanged and serum
potassium levels were unaltered [Day 1 (mmol/liter) 3.9 (3.8 to
4.0) vs. 3.8 (3.7 to 3.9), placebo vs. cyclosporine; Day 4
(mmollliter) 4.0 (3.8 to 4.2) vs. 4.1 (4.0 to 4.2), placebo vs.
cyclosporine].
Renal hemodynamics, blood pressure and renal vascular
resistance. GFR and ERPF were not significantly altered by
cyclosporine therapy (Table 3, Fig. 1). Both systolic and
diastolic components contributed to the sustained increase in
mean arterial pressure which began rising on day 1. Renal
vascular resistance increased along with the blood pressure.
Hormonal changes. Neither ANP nor vasopressin was al-
tered by cyclosporine compared to placebo during the four days
of therapy. Whereas there was significant suppression of the
renin-angiotensin axis from day 2 onwards which was dissoci-
ated from aldosterone (Table 5).
Study 2
Renal water and electrolyte handling. The antidiuretic effect
of cyclosporine was augmented by the vasopressin infusion
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Table 3. Hemodynamic and renal water handling effects of cyclosporine and placebo on days 1 and 4
Dayl Day4
Placebo Cyclosporine Placebo Cyclosporine
Pre Post Pre Post Pre Post Pre Post
UV 17.4 19.3 18.2 14.7a 18.5 18.2 14.8a l2.4
mI/mm (15. 1—19.7) (16.0—22.6) (15.8—20.6) (11.8—17.6) (16.0—21.0) (16.0—20.4) (12.8—16.8) (10.5—14.3)
Uosm 61 58 62 94 60 59 84 l24
mOsm/kg JI2O (56—66) (52—64) (53—71) (60—127) (54—66) (50—68) (72—96) (88—159)
CH2O
mi/mm
15.2
(12.9—17.5)
15.8
(13.0—18.6)
16.6
(14.2—19.0)
I0.9a
(8. 1—13.7)
16.7
(13.9—19.5)
14.6
(12.4—16.8)
l1.7a
(9.7—13.7)
73
(5.2—9.4)
GFR 110 108 99 99 108 106 104 100
mi/mm (102—108) (100.—I 16) (90—108) (91—107) (100—116) (97—115) (96—112) (91—109)
ERPF 632 486 571 446 667 654 630 579
mI/mm (560—704) (319—653) (500—642) (321—571) (600—734) (595—713) (568—692) (533—625)
RVR 9.3 8.8 10.3 Io.sa 8.8 9.2 10.3 11.4a
mm Hg/mI/mm (7.9—10.7) (7.6—10.0) (8.9—11,7) (9.0—12.0) (7.4—10.2) (7.7—10.7) (8.6—12.0) (10.0—12.8)
HR 63 66 60 64
beats/mm (56—70) (60—72) (53—67) (59—69)
a P < 0.05 vs. cyclosporine.
Day2 Day3
Placebo Cyclosporine Placebo Cyclosporine
Total urine output 2448 l238 1240 1166
ml (1879—3016) (829—1647) (801—1679) (1104—1228)
Total UNa output 114 150 139 188
mmol/day (78—150) (95—205) (99—180) (124—252)
Total UK output 69 60 37 37
mmol/day (52—86) (42—78) (22—67) (11-63)
with the combination of cyclosponne and vasopressin signifi-
cantly reducing urine volume production and free water clear-
ance and increasing urine osmolality compared to all other
treatment regimens (Table 6, Fig. 2).
Renal hemodynamics, blood pressure and renal vascular
resistance. The vasopressin infusion did not significantly alter
either GFR or ERPF nor influence the effect of cyclosponne on
these parameters (Table 6). The vasopressin infusion had no
systemic pressor effect.
Discussion
Primarily this study found that: (1) cyclosponne exerted an
early hypertensive effect which preceded the development of
any change in GFR or ERPF, but occurred coincidentally with
a rise in renovascular resistance; (2) This hypertension was not
associated with evidence of renal sodium retention. Our study
therefore casts doubt on the hypothesis of Luke [18] regarding
the pathogenesis of cyclosponne induced hypertension and
nephrotoxicity; (3) An antidiuretic effect of cyclosponne was
apparent which was not due to stimulation of vasopressin
levels. Finally, our study contradicts work by another group
[24] concerning the rapidity of onset of acute cyclosponne-
induced nephrotoxicity.
In these studies, cyclosporine was administered orally at the
recommended initiating dose for patients [25]. The peak and
trough drug levels attained in our study are comparable to
therapeutic levels in patients [26]. Hypertension was a promi-
nent finding during the first four days of cyclosponne therapy.
In particular, the blood pressure increased significantly within a
few hours of the first administered dose of cyclosponne.
Long-term studies in patients with cyclosporine induced hyper-
tension have suggested that sodium retention and increased
extracellular fluid volume are mediators of the blood pressure
increase [18, 27] and that these effects follow as a result of renal
vasoconstnction. In our study, blood pressure rose before
either sodium retention or renal dysfunction could occur. These
findings are therefore incompatible with the unifying hypothesis
of Luke [19] regarding the pathogenesis of nephrotoxicity and
hypertension. We found complex effects of cyclosponne on
renal sodium balance. This study, as other workers have
suggested, found that cyclosponne increases proximal Na
reabsorption [28]. However, although there was a statistically
Table 4. Twenty-four hour urine collection results on days 2 and 3
for cyclosporine and placebo
a P < 0.05 vs. placebo.
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Fig. 1. The blood pressure effect of cyclosporine () over the first four
days of therapy is compared to placebo (D). 'Post" measurements
were taken 4 hours post-morning dose. *fl < 0.05 compared to placebo.
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T
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Table 5. Sequential hormonal effects of cyclosporine and placebo
Baseline Day 1 Day 2
Placebo Cyclosporine Placebo Cyclosporine Placebo Cyclosporine
Plasma renin activity ng/mi/hr 1.17 0,89 0.77
(0.19—2.15) (0.33—1.87) (0.57—0.97)
0.60 1.37
(0.42—0.78) (1.03—1.71)
0.64a
(0.22—0.98)
Plasma aldosterone pg/mi 194.4 172.8 127.7
(117.2—271.6) (131.4—214.2) (90.4—164.9)
132.6 185.4
(106.0—159.2) (132.3—238.5)
142.4
(107.4—177.4)
Serum angiotensin II pg/mi 20.4 24.9 22.4
(15. 1—25.7) (18.5—3 1.3) (15.2—29.6)
21.6 40.8
(18.2—25.0) (29.0—52.6)
20.9a
(15.6—26.2)
Plasma vasopressin pmoi!Iiter 0.87 1.07 1.28
(0.63—1.11) (0.54—1.60) (0.77—1.79)
1.31 2.22
(0.82—1.80) (1.34—3.10)
1.35
(0.94—1.76)
Plasma atrial natriuretic factor pmoi/iiter 7.24 7.54 7.31
(5.65—8.85) (6.25—8.83) (5.06—9.56)
8.49 7.75
(6.82—10.16) (6.79—8.71)
7.72
(5.43—10.01)
Urinary prostaglandin E2 pg/mi
a P < 0.05 vs. placebo.
Table 5. Continued
Day3
Placebo Cyclosporine
Day4
Placebo Cyclosporine
Plasma renin activity ng/ml/hr 1.60 0.42a
(1.49-1.71) (0.20—0.64)
1.96
(1.72—2.19)
o.2oa
(0.10—0.30)
Plasmaaldosteronepg/mi 212.5 1l9.5a
(179.9—245.1) (105.4—133.6)
113.5
(85.5—141.5)
117.3
(98.8—135.8)
Serum angiotensin II pg/mi 45.9 23.4a
(33.9—57.9) (14.1—32.7)
23.0
(17.4—28.6)
14.6a
(11.3—17.9)
Plasma vasopressin pmoi!iiter 1.28 1.32
(0.57—1.99) (0.83—1.81)
0.67
(0.49—0.85)
0.92
(0.67—1.17)
Plasma atrial natriuretic factor pmoi/iiter 8.20 9.06
(6.65—9.75) (8.29—9.82)
6.87
(5.54—8.20)
9.02
(7.09—10.94)
Urinary prostaglandin E2 pg/mi 20.8
(16.4—25.2)
23.6
(5.0—42.2)
a P < 0.05 vs. placebo.
Table 6. Interaction of vasopressin with cyclosporine on blood
pressure, renal hemodynamic parameters and water handling
Placebo/ Cyclosporine/ Placebo! Cyclosporine!
placebo placebo vasopressinvasopressin
Uosm 62 l20 417a,b 622a,b,c
mOsm!kg
CH2O
mi/mm
(58—66)
12.9
(11.2—14.6)
(71—169)
7.la
(4.9—9.3)
(271—563)
04a.b
(—1.5—2.3)
(503—741)
(—2.l——0.7)
GFR 98 104 85 101
mi/mm (78-118) (50—158) (63—108) (84-118)
ERPF 551 548 510 507
mi/mm (430—672) (359—737) (419—601) (406—608)
RVR 10.3 13.9a 11.6 12.7
mm Hg! (8.7—11.9) (10.9—16.9) (8.5—14.7) (10.1—15.3)
mi/mm
MAP 90 103 92 l0l'
mm Hg (82.5—97.5) (96-110) (85—99) (96—106)
a P < 0.05 vs. placebo.
b P < 0.05 vs. cyclosporine alone.
C P < 0.05 vs. vasopressin alone.
significant increase from baseline, the absolute values were not
different from placebo. This proximal tubular sodium reabsorp-
tion clearly developed after hypertension was manifest. This
increase in proximal Na reabsorption would inevitably pro-
duce a fall in delivery of Na to the diluting segments in the
present study. However, Na reabsorption in the ascending
limbs of the long loops of Henle is directly dependent upon Na
delivery. Therefore, for there to have been a net reduction in
Na reabsorption and thus a natriuresis (as we found), the
nephrons involved must have been the short-looped superficial
cortical ones rather than long-loop "sodium retentive" neph-
rons. Thus, the tendency for proximal Na reabsorption which
cyclosporine induced was overcome in terms of the overall
urine Na output by other effects. Speculation about the mech-
anisms for this might include pressure natriuresis or a redistri-
bution of intrarenal blood flow consequent upon angiotensin II
suppression. We have confirmed observations from many pa-
tient studies that the renin-angiotensin axis is suppressed during
cyclosporine administration, but this may simply be in response
to the hypertension which occurred. There is evidence that this
situation changes with time. Balletta et al found that cyclospo-
rine induced renal vasoconstriction and a consequent reduced
GFR, reduced the NAF and NaRProx % and increased the
NaRDiI %, but they did not quantify any actual changes in renal
sodium output [23].
The initiating stimulus for cyclosporine induced hypertension
remains unknown. We found that heart rate per se did not
change, which is tentative evidence against sympathetic ner-
vous system activation in the pathogenesis of cyclosporine
induced hypertension. Further, a systemic effect of vasopressin
as a direct vasoconstrictor seems unlikely in view of our finding
that vasopressin did not increase the systemic blood pressure
when administered with cyclosporine therapy in spite of its
augmenting the antidiuresis. Endothelin is another contender
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Fig. 2. The effects of cyclosporine and placebo before and after
infusion of placebo or vasopressin. Symbols are: (D) Placebo/placebo;()Cyclosporine/placebo;() Placebo/vasopressin; () Cyclosporine/
vasopressin. < 0.05 compared to placebo alone; +P < 0.05
compared to cyclosporine alone; #P < 0.05 compared to vasopressin
alone.
which was not addressed in this present study but which other
work has suggested may have a role [15, 29, 30]. It seems less
likely that any initiating factors could, however, continue to act
to maintain hypertension without renal involvement in the long
run. Guyton, for example, believes that all systemic vasocon-
strictors must act via the kidneys and salt/water balance for
hypertension to be sustained [31].
Cyclosporine induced a significant antidiuretic effect which
was most marked under the conditions of waterloading. This
was progressive in that the stimulated urine production on day
4 was significantly different from placebo and day 1 cyclospo-
rine peak effect. However, this antidiuretic effect was not
consistently sustained over a full 24 hour period. Further, if it
had been sustained, vasopressin levels and ANP levels should
have been suppressed, but they were not. It therefore may be a
peak drug effect which we were observing. Similarly, it has
been suggested that cyclosporine-induced renal vasoconstric-
tion is a transient phenomenon occurring only at peak drug
concentration [32]. Free water clearance is regulated in two
main ways: by alterations in glomerular filtration rate or by the
action of vasopressin on the distal tubule. In these studies, GFR
did not vary and therefore did not account for the altered renal
water handling. The role of vasopressin was investigated by
measuring levels of the hormone on successive days. The water
loading regimen should suppress vasopressin activity [19].
Vasopressin levels in hydrated subjects are documented as
ranging between 0.4 and 3.7 pg/ml [331 and water loading may
not be able to lower these vasopressin levels any further [34]. In
our study, the levels of vasopressin on placebo and cyclospo-
rine were not significantly different and were within the normal
range as stated above. It seems likely from our studies that
cyclosporine either augmented the distal nephron effect of
unchanged levels of vasopressin or that cyclosporine has a
direct antidiuretic effect itself irrespective of vasopressin. An
alternative explanation is that cyclosporine induced a redistri-
bution of blood flow in the vasa recta which could account for
both the sodium and water handling effects which we observed.
Our data do not support animal and some patient studies which
have previously suggested a role for vasopressin in the induc-
tion of nephrotoxicity by cyclosporine. A study involving
Brattleboro rats (a genetic strain lacking endogenous vasopres-
sin) found that they were relatively protected from cyclospo-
rime-induced renal dysfunction [35]. In humans, a group of renal
transplant recipients has been studied shortly after commence-
ment of cyclosporine therapy and have been found to have
vasopressin levels in the upper range of normal [36]. Unfortu-
nately, pre-treatment levels of the hormone in this group were
not measured and renal transplant patients tend to have raised
vasopressin level anyway [37]. Vasopressin and cyclosporine
could interact at many levels, including prostaglandin E2 [38],
glomerular mesangial cells [39, 40] or calcium fluxes [41, 42]. It
is, therefore, still possible that cyclosporine and vasopressin
interact further over time to induce more renal dysfunction than
just the exaggerated antidiuresis which we observed.
Our observation that cyclosporine did not change the renal
hemodynamic parameters of GFR and ERPF came as a surprise
in view of previous studies. Our findings contradict the work of
Conte et al [241, who gave a single dose of cyclosporine to
healthy men and found that it reduced both the GFR and ERPF
within two hours in ingestion. It is worth noting that in Conte's
study there was no placebo day. Further, in a subsequently
reported study the same group could not consistently reproduce
this GFR change under similar conditions [42]. In another
study, a single intravenous dose of cyclosporine induced a small
but significant decrease in GFR without affecting ERPF, but
this preparation contained the potent vasoconstrictor, crema-
phor EL [43]. The lack of change in ERPF and GFR which we
found agrees with a previous study of our own [44], but why our
two studies do not agree with Conte et al's first study is not
clear. One possible, albeit unlikely, explanation relates to the
fact that we gave the cyclosporine along with food. Protein
feeding (105 g) is known to cause renal vasodilation and a 27%
increase in GFR within 150 minutes [45], possibly via dietary
arginine being converted into nitric oxide [46]. In fact, the meal
which we gave our volunteers was principally fat (15 g) to help
cyclosporine absorption and contained very little protein (<10
g). Nevertheless, in giving cyclosporine with food, the way
cyclosporine is given in clinical practice was mimicked. Indeed,
in one other study on the effect of cyclosporine on renal
function, changes in GFR and ERPF did not become apparent
until between one and two weeks of therapy with cyclosporine
[47]. However, the lack of change in GFR and ERPF may well
suggest that compensatory mechanisms are operative. Indeed,
if there were an increase in renal perfusion pressure secondary
to systemic hypertension and an unchanged afferent arteriolar
resistance, then the GFR ought actually to rise. Therefore,
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since the GFR was unchanged, it is likely that there was a subtle
increase in afferent arteriolar resistance presumably due to
vasoconstriction.
It is therefore apparent that there is a vast difference between
the long-term effects of cyclosporine on blood pressure, renal
function and hormones and those which occur soon after
commencement of cyclosporine therapy. Drug intervention
against the early effects of cyclosporine may prove more
successful than trying to combat the late secondary effects of
cyclosporine therapy once they are established.
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